Home › Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy clinical trials recruiting in the U.S.
16 studies for Hypertrophic Cardiomyopathy are recruiting participants at sites across the United States.
Cities with the most studies
- Boston, MA6 studies
- Cleveland, OH4 studies
- Charlottesville, VA4 studies
- San Francisco, CA4 studies
- New York City, NY3 studies
- San Diego, CA3 studies
- Houston, TX3 studies
- Chicago, IL3 studies
By state
- California7 studies
- Illinois4 studies
- Massachusetts6 studies
- Michigan3 studies
- Minnesota3 studies
- Missouri3 studies
- New York4 studies
- North Carolina3 studies
- Ohio4 studies
- Pennsylvania3 studies
- Texas3 studies
- Virginia4 studies
Recently updated studies
Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy
RecruitingPhase 2
Ages 6 and older · All sexes · Updated Sep 2, 2026 · NCT07721025A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT05489705Study of the Progression of Chronic Cardiovascular Conditions
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT07420907Cardiovascular Multimodality Imaging Study
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT06610019Pediatric Cardiomyopathy Mutation Analysis
RecruitingObservational study
All ages · All sexes · Updated Jun 22, 2026 · NCT02432092Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
RecruitingObservational studyHealthy volunteers welcome
Ages 50 and older · All sexes · Updated Jun 4, 2026 · NCT06034405Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
RecruitingPhase 4
Ages 18 to 90 · All sexes · Updated May 20, 2026 · NCT07600177A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 18, 2026 · NCT07023614A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease
RecruitingPhase 2
Ages 8 and older · Men · Updated May 4, 2026 · NCT06092034Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Mar 19, 2026 · NCT05836259HCMR Re-Imaging Study
RecruitingObservational study
Ages 18 to 65 · All sexes · Updated Mar 18, 2026 · NCT07054073Exercise Intolerance in Non-obstructive Hypertrophic Cardiomyopathy
Recruiting
Ages 18 to 80 · All sexes · Updated Nov 20, 2025 · NCT05818605Mavacamten Pregnancy Surveillance Program
RecruitingObservational study
Ages 15 and older · Women · Updated Nov 6, 2025 · NCT05939700Large Language Models To Improve the Quality of Care of Cardiology Patients
Recruiting
Ages 18 and older · All sexes · Updated May 15, 2025 · NCT06935253Real-world Patient Reported Outcomes Among Patients Treated With Camzyos
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 7, 2024 · NCT06551129Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM
RecruitingObservational study
Ages 18 to 85 · All sexes · Updated Nov 6, 2024 · NCT06023186From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.